Genprex, Inc. (GNPX) Form 10-Q — Aug 14, 2026
Genprex filed its Q2 2026 10-Q reporting no revenue, a quarterly net loss of $4.4 million ($8.9 million for the first half), and cash of $15.2 million at June 30, 2026, up from $7.8 million at year-end after roughly $15.6 million of ATM equity sales during the half. The company disclosed substantial doubt about its ability to continue as a going concern, stating current cash funds operations only into the second half of 2027 and that additional capital is required. It sold a further 241,000 shares for about $1.53 million after quarter-end, continuing its reliance on ATM equity issuance.
Key figures
- Revenue
- 0
- Total Assets
- 17136916
- Cash Position
- 15154203
- Shares Outstanding
- 819709
- Cash runway
- into the second half of 2027
- Eloc commitment
- 12500000
- Total liabilities
- 2341864
- Q2 2026 ga expense
- 1800513
- Cash at dec 31 2025
- 7830855
- Q2 2026 rnd expense
- 2683471
- Stockholders equity
- 14795052
- Cash above fdic limits
- 14904167
- Atm net proceeds h1 2026
- approximately $15.6 million on 353,095 shares
- Reverse split 2025 ratio
- 1-for-50 (effective October 21, 2025)
- Reverse split 2026 ratio
- 1-for-22 (effective July 16, 2026)
- Shares outstanding basis
- 819,709 shares as of August 10, 2026 per cover page; 506,218 shares at June 30, 2026
- Atm net proceeds post quarter
- approximately $1.53 million on 241,000 shares (July 1, 2026 through filing date)
Price after filing
Close on the filing date to close N calendar days later (from $4.32). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.